Zynex (ZYXI) to Release Earnings on Monday

Zynex (NASDAQ:ZYXI) is anticipated to release its Q4 2025 results after the market closes on Monday, April 27th. Analysts expect Zynex to post earnings of ($0.15) per share and revenue of $22.60 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, April 9, 2026 at 4:00 PM ET.

Zynex Stock Performance

ZYXI stock opened at $0.13 on Friday. The business’s fifty day moving average is $0.12 and its 200-day moving average is $0.46. The company has a quick ratio of 0.32, a current ratio of 0.47 and a debt-to-equity ratio of 0.56. The company has a market cap of $3.80 million, a P/E ratio of -0.05 and a beta of 0.99. Zynex has a twelve month low of $0.12 and a twelve month high of $2.82.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Engineers Gate Manager LP acquired a new position in shares of Zynex in the 2nd quarter valued at $32,000. XTX Topco Ltd acquired a new position in shares of Zynex in the 2nd quarter valued at $47,000. Sender Co & Partners Inc. acquired a new position in shares of Zynex in the 2nd quarter valued at $67,000. Bridgeway Capital Management LLC acquired a new position in shares of Zynex in the 2nd quarter valued at $108,000. Finally, Marshall Wace LLP acquired a new stake in Zynex during the 2nd quarter worth $131,000. Institutional investors and hedge funds own 29.68% of the company’s stock.

Zynex Company Profile

Zynex, Inc is a medical device company engaged in the design, development, manufacture and sale of non-invasive therapeutic and patient monitoring equipment in the United States. Headquartered in Englewood, Colorado, the company focuses on delivering FDA-cleared solutions aimed at pain management, neurological rehabilitation and remote patient monitoring. Zynex’s portfolio is structured to address the needs of healthcare providers, outpatient clinics and patients receiving care in their homes.

The company’s core product offerings include electrotherapy devices—such as transcutaneous electrical nerve stimulation (TENS) and neuromuscular electrical stimulation (NMES) systems—designed to alleviate pain and assist in muscle recovery.